|
SCIENTIFIC
PROGRAMME
The
Scientific Programme comprises Plenary Lectures, Mini-Symposia,
Poster Sessions and Parallel Lecture Sessions. Two
Hot Topic Discussion Sessions will focus on contemporary
issues. All scientists working in any field of the pharmaceutical
sciences are cordially invited to submit an Abstract of their
work for presentation at EUFEPS 2000. The list of Session Topics
and format instructions for Abstracts are given in the Call
for Papers section. The deadline for submission of Last-Minute Posters is 1 September, 2000. Abstracts for Last-Minute Posters will be available to delegates in a Supplementary Abstract Book. All other accepted Abstracts submitted previously will be published in a special supplement of the European Journal of Pharmaceutical Sciences.
Details of Posters to be presented in each Session are given in the List of Posters.
Saturday, 16th September
| 8.00 | | Registration, Workshops, Courses |
| 19.30 | | Welcome Reception in National Gallery |
Sunday, 17th September
Welcome Session and Plenary Lectures
| 10.00 | Welcome Ceremony, Presentation of Medals, Awards |
| 11.00 | PL-1 | B. Testa, P. Crivori, S. Rey, G. Cruciani and P.A. Carrupt (Lausanne, Switzerland - Perugia, Italy):
Pharmacokinetic Optimization of Lead Compounds - The New Challenge
|
| 11.45 | PL-2 | B. Wetzel (Ingelheim, Germany):
High Throughput Screening and Molecular Diversity: New Paradigms in Drug Discovery
|
| 12.25 | Lunch Break, Exhibition |
| 13.30 | Authors in attendance at their posters |
Mini-Symposium 1:
NEW PERSPECTIVES IN NATURAL PRODUCT CHEMISTRY
| 15.00 | MS-1 | K. Hostettmann (Lausanne, Switzerland):
The Potential of Plants as a Source of New Drugs
|
| 15.30 | MS-2 | R. Verpoorte (Leiden, The Netherlands):
Metabolic Pathway Engineering: New Ways to Known and Novel Plant Compounds
|
| 16.00 | Coffee Break |
| 16.30 | MS-3 | Cs. Szántay (Budapest, Hungary):
Synthesis of Biologically Active Natural Products
|
| 17.00 | Discussion |
Session 1:
PHYSICOCHEMICAL ASPECTS OF DRUG ACTION
| 15.00 | KN-1 | K. Valkó, C.M. Du, C. Bevan, D.P.Reynolds and M.H. Abraham (Stevenage, London, UK):
High Throughput Measurements of Lipophilicity for Combinatorial lead optimisation
|
| 15.30 | O-1 | M. Plass, K. Valkó and M.H. Abraham (Halle, Germany; Stevenage, London, UK):
Determination of Solute Descriptors From High-Throughput HPLC Retention Data |
| 15.50 | O-2 | R. Kaliszan, P. Haber and T. Baczek (Gdansk, Poland):
Gradient HPLC as a Convenient Method of Determination of Lipophilicity (log kw) and Acidity (pKa) |
| 16.10 | Coffee Break |
| 16.40 | O-3 | F. Wohnsland and B. Faller (Basel, Switzerland):
Prediction of Gastro-intestinal Drug Absorption Using a Hexadecane Barrier as an Artificial Model Membrane |
| 17.00 | O-4 | S.D. Krämer, A. Braun, K. Käser, C. Forster, C. Ottiger, M. Birringer, A. Johayem, D.J. Begley, N.J. Abbott and H. Wunderli-Allenspach (Zürich, Switzerland; London, UK):
The Implications of Lipid Diversity in Biological Membranes for the In Vivo Passage of Drugs |
| 17.20 | O-5 | B. Noszál (Budapest, Hungary):
Novel Physico-chemical Parameters of Pharmaceutical Importance |
Session 2:
NOVEL CONCEPTS IN DOSAGE FORM DESIGN
| 15.00 | KN-2 | H.G.Kristensen (Copenhagen, Denmark):
Oral Delivery of Low Solubility Drugs
|
| 15.30 | O-6 | I.M. Van der Lubben, F.A.J.Konings, J.C. Verhoef and H.E. Junginger (Leiden, The Netherlands):
Porous Chitosan Microparticles for Oral Vaccination: in Vivo Uptake by Murine Peyer's Patches |
| 15.50 | O-7 | C. Caramella and M.C. Bonferoni (Pavia, Italy):
Functionality of Excipients for Controlled Release |
| 16.10 | Coffee Break |
| 16.40 | O-8 | I. Csóka, K. Sütö, P. Sipos and I. Erös (Szeged, Hungary):
Characterization of Multiple Emulsions |
| 17.00 | O-9 | M. Renouard and M.-A. Perrin (Vitry sur Seine, France):
Paracetamol Particle Properties and Their Impact on Tabletting. Investigation of Capping Defaults on Compacts Using Industrial Rotary Press
|
| 17.20 | O-10 | C. Castan, R. Meyrueix, M. Gicquel, P. Autant, R. Jorda and G. Soula (Vénissieux, France):
GenvirTM: The First Sustained Release Dosage Form of Acyclovir |
POSTER SESSION 1
Monday, 18th September
Mini-Symposium 2:
MODELLING DURING DRUG DEVELOPMENT: IN VITRO / IN VIVO MODELLING OF DRUG ABSORPTION, METABOLISM AND RECEPTOR BINDING (A COST B15 SYMPOSIUM)
| 9.00 | MS-4 | L.P. Balant, A. Boobis and O. Pelkonen (Geneva, Switzerland):
In Vitro/In Vivo Modelling of Xenobiotic Metabolism |
| 9.30 | MS-5 | M. Durisová (Bratislava, Slovak Republik):
System Approach for Modelling In Vitro/in Vivo Drug Absorption |
| 10.00 | MS-6 | I. Sylte, A. Boronowska and S.G. Dahl (Tromso, Norway - Warsaw, Poland):
Molecular Modelling of Drug-Receptor Interactions |
| 10.30 | MS-7 | M. Danhof, P.H. Van der Graaf, E.H. Cox, A. Cleton, M. Garrido and K.P. Zuidveld (Leiden, The Netherlands):
In Vitro/InVivo Modelling of Receptor Mediated Pharmacological Response |
| 11.00 | Discussion |
Session 3:
KEY ISSUES IN DRUG ANALYSIS
| 9.00 | KN-3 | J.C. Berridge (Sandwich, UK):
Analytical Strategies for Drug Development |
| 9.30 | O-11 | G. Blaschke (Münster, Germany):
Assay of Drugs and Drug Metabolites in Biological Samples by Capillary Electrophoresis (CE) |
| 9.50 | O-12 | A. Van Schepdael, E. Roets and J. Hoogmartens (Leuven, Belgium):
Capillary Electrophoresis of Antibiotics: Selected Examples |
| 10.10 | Coffee Break |
| 10.40 | O-13 | L.J. Veuthey, L. Geiser, D. Ortelli, S. Souverain, S. Rudaz and E. Varesio (Geneva, Switzerland):
High Throughput Analyses in Pharmacy |
| 11.00 | O-14 | A.F. Fell and M.A.K. Azad (Bradford, UK):
Impact of Unusual Degradation Products from Ester-Polyol Excipients on Drug Assay Validation Status |
| 11.20 | O-15 | H.J. Leis, W. Windischhofer, G. Fauler and G. Raspotnig (Graz, Austria):
Gas Chromatography - Negative Ion Chemical Ionization Mass Spectrometry in Drug Analysis |
Session 4:
CHALLENGES IN NATURAL PRODUCT CHEMISTRY AND PHYTOTHERAPY
| 9.00 | KN-4 | T. Dingermann (Frankfurt, Germany):
Phytotherapy: could less be more? |
| 9.30 | O-16 | C.W. Jefford (Geneva, Switzerland):
Artemisinin and New Peroxidic Antimalarials |
| 10.00 | O-17 | P. Vuorela, M. Leinonen, P. Saikku and H. Vuorela (Helsinki - Oulu, Finland):
Interactions of Phenolic Compounds with Chlamydia Pneumoniae-Infection in HL-Cells |
| 10.20 | Coffee Break |
| 10.40 | O-18 | G. Bonn (Innsbruck, Austria):
New Developments and Applications of Modern Chromatographic Methods for the Analysis of Natural Products |
| 11.00 | O-19 | A. Czompa, Z. Dinya, E. Baitz-Gács, Zs. Varga, S. Antus and Sz. Nyiredy (Debrecen - Budapest - Budakalász, Hungary):
Isolation, Structure Elucidation and Antioxidant Activity of Flavonoid Derivatives Containing a 1,4 Benzodioxane Moiety |
| 11.20 | O-20 | M. Wurglics, K. Westerhoff, A. Kaunzinger, M. Schubert-Zsilavecz, A. Baumeister and J.B. Dressman (Frankfurt - Neu-Ulm, Germany):
Biopharmaceutical Characterisation of New High Dosage St. John's Wort Products |
INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL (IPEC) SYMPOSIUM
(Part 1)
| 9.00 | IP-1 | R. Bass (London, UK):
Regulatory Requirements for New Excipients |
| 9.30 | IP-2 | H. De Jong (Courbevoie, France):
Randomly Methylated ß-Cyclodextrin, a New Excipient |
| 10.00 | Coffee Break |
| 10.40 | IP-3 | J.H. Trouvin (Paris, France):
BSE/TSE in Relation to Pharmaceuticals in Europe |
| 11.10 | IP-4 | J.H. Trouvin (Paris, France):
Development of a Prion Test to Detect Risk of Infection |
Plenary Lecture
| 11.45 | PL-3 | R. Duncan (London, UK):
Polymer Therapeutics: Targeting Drugs and Genes to Tumours |
| 12.25 | Lunch Break, Exhibition |
| 13.15 | Authors in attendance at their posters |
Mini-Symposium 3:
GENOME BASED DRUG DISCOVERY
| 14.30 | MS-8 | Ch. Noë (Vienna, Austria):
Chemistry of Antisense Nucleotides |
| 15.00 | MS-9 | P.E. Nielsen (Copenhagen, Denmark):
Peptide Nucleic Acid (PNA). Towards Gene Therapeutic Drugs |
| 15.30 | Coffee Break |
| 16.00 | MS-10 | Gy. Kéri (Budapest, Hungary):
Signal Transduction Therapy: New Trends in Drug Research |
| 16.30 | Discussion |
Session 5:
CHIRAL ISSUES IN DRUG ANALYSIS
| 14.30 | KN-5 | W. Lindner (Vienna, Austria):
Molecular Recognition and Enantioselective Analysis: Concepts and Needs |
| 15.00 | O-21 | J. Crommen, A. Abushoffa, M. Fillet and Ph. Hubert (Liège, Belgium):
Enantiomeric Separation of Drugs by Capillary Electrophoresis Using Dual Cyclodextrin Systems |
| 15.20 | O-22 | B.J. Clark (Bradford, UK):
Chiral Drug Screening with Capillary Electrophoresis and Electrochromatography |
| 15.40 | Coffee Break |
| 16.10 | O-23 | M. Gazdag, M., T. Takács and É. Szöllösi (Budapest, Hungary):
Optimization of Enantioseparation of Norgestrel by Capillary Electrochromatography |
| 16.30 | O-24 | G. Tárkányi (Budapest, Hungary):
Chiral Discrimination by NMR Using Cyclodextrins |
| 16.50 | O-25 | Á. Demeter, G. Tárkányi, T. Gáti, É. Szentirmay, I. Greiner, Gy. Kalaus and Cs. Szántay (Budapest, Hungary):
How to Obtain Enantiomeric Ratios by NMR in Solution-Phase Without Any Chiral Additives. A Case Study |
Session 6:
ISSUES IN PK/PD AND TOXICOLOGY
| 14.30 | KN-6 | W. Jusko (Buffalo, USA):
Diversity in Pharmacokinetic-Pharmacodynamic Modelling |
| 15.00 | KN-7 | J. Doehmer, N. Krebsfänger, W. Schober, L. Wojnowski and G. Heinrich (München, Germany):
Issues in ADME and Drug Toxicology |
| 15.30 | O-26 | I.A. Nestorov, T. Yates and M. Rowland (Manchester, UK):
Incorporating Measures of Physiological Variability into Physiologically Based Pharmacokinetic Modelling |
| 15.50 | Coffee Break |
| 16.10 | O-27 | I. Gueorguieva, I. Nestorov, M. Rowland and E. Hüllenmeier (Manchester, UK - Toulouse, France):
In Vitro/In Vivo Hepatic Clearance Prediction Using Fuzzy Sets |
| 16.30 | O-28 | I. Eder, J. Schueller, M. Czejka, U. Zeleni and C. Wetschka (Vienna, Austria):
Pharmacokinetics (PHK) and Metabolism of Epirubicin (EPI) in Combination with Docetaxel (TXT): In Vivo/In Vitro Correlation |
| 16.50 | O-29 | M. Czejka, J. Schueller, I. Eder, B. Ehn, U. Zeleni and R. Freitag (Vienna, Austria):
Clinical Pharmacokinetics and Metabolism of Paclitaxel Combined with the Cytoprotective Agent Amifostine (Ethyol ®) |
INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL (IPEC) SYMPOSIUM
(Part 2)
| 14.30 | IP-5 | M. Ten Ham (The Hague, The Netherlands):
Global Impact of ICH Standards |
| 15.00 | IP-6 | A. Artiges (Strasbourg, France):
The European Pharmacopoeia Certification of Suitability Procedures |
| 15.30 | Coffee Break |
| 16.00 | IP-7 | M. Dixon (Windlesham, UK):
Development of ICH Guidance on Good Manufacturing Practice |
| 16.30 | IP-8 | O. Gross (Saint-Denis, France):
Good Manufacturing Practices Inspections for Starting Materials |
Hot Topic Discussion Session A:
NEW SAFE MEDICINES FASTER
| 17.15 | Panel: | O.J. Bjerrum (Copenhagen, Denmark, Chair)
L. de Leede (Leiderdorp, The Netherlands)
S. Wicks (Sandwich, UK) |
Hot Topic Discussion Session B:
NEW DEVELOPMENTS IN ALZHEIMER¹S DISEASE: FOCUS ON INFLAMMATION
| 17.15 | Panel: | E. Mutschler (Frankfurt, Germany, Chair)
Z. Rakonczay (Szeged, Hungary)
|
POSTER SESSION 2
Tuesday, 19th September
Mini-Symposium 4:
MATERIAL SCIENCE AND DRUG DESIGN
| 9.00 | MS-11 | C. Bogentoft (Stockholm, Sweden):
Industrial Perspective on the Design of Drug Delivery Systems |
| 9.30 | MS-12 | M. Vert (Montpellier, France):
Macromolecular Prodrugs from Artificial Metabolite-Based Polymeric Backbones |
| 10.00 | Coffee Break |
| 10.30 | MS-13 | R.T. Forbes (Bradford, UK):
Solid State Characterisation of Drug/Fatty Acid Systems for Oral Delivery |
| 11.00 | Discussion |
Session 7:
REGULATORY, VALIDATION AND OTHER ISSUES
| 9.00 | KN-8 | R. Bass (Berlin, Germany; London, UK):
Streamlining Drug Development: Mainstream and Ups and Downs |
| 9.30 | O-30 | T. Paál (Budapest, Hungary):
Regulatory Affairs in the Central and Eastern European Countries |
| 9.50 | O-31 | L. Endrényi, L. Tóthfalusi and J. Zha (Toronto, Canada; Budapest, Hungary):
Measures for Determining the Bioequivalence of Early-Phase Concentration-Time Profiles |
| 10.10 | Coffee Break |
| 10.40 | O-32 | P. Perjési and I. Ember (Pécs, Hungary):
Studies on Anticarcinogenic Effect of Cyclic Chalcone Derivatives |
| 11.00 | O-33 | A.C. Hillisch and H. Oelschläger (Jena, Germany):
Stability Investigations of Long-term Stored Drug Substances |
| 11.20 | O-34 | V. Rizzo (Nerviano, Italy):
Development of Anticancer Drug-Polymer Conjugates: the Challenge of Analytical Characterization |
Session 8:
STRATEGIES FOR DRUG DESIGN AND DEVELOPMENT
| 9.00 | KN-9 | D.D. Breimer (Leiden, The Netherlands):
Novel Concepts and Strategies in the Development of New Drugs |
| 9.30 | O-35 | M. Glänzel, R. Bültmann, K. Starke and A.W. Frahm (Freiburg, Germany):
Development of Potent and Selective P2-Receptor Anatagonists. Synthesis, Biological Characterisation and Structure-Activity-Relationships |
| 10.00 | O-36 | P.H. Andersen (Valby, Denmark):
Peptide Mimics - Experience from Successful Projects |
| 10.20 | Coffee Break |
| 10.50 | O-37 | B. Resul and J. Stjernschantz (Uppsala, Sweden):
Prostaglandins as Potent Antiglaucoma Agents. From Chemistry to Patient Use |
| 11.10 | O-38 | W.H. Greb (Neuss, Germany):
Proof of Concepts in Early Drug Development |
Closing Session and Plenary Lecture
| 11.45 | PL-4 | G. Gaviraghi (Verona, Italy):
Glycine Receptor Anatagonists: Synthesis, structure Activity Relationship and Therapeutic Applications |
| 12.30 | Presentation of Poster Awards
Closing remarks
Invitation to EUFEPS 2002 Congress, Stockholm
|
|
.gif){kind=small}
.gif){kind=small}